A lack of big pharma licensing deals and IPOs created problems, but newer UK biotech companies moved ahead in 2024 thanks to increased venture capital funding, finds a new report from the BIA.
The UK remains the best capitalized European biotech sector but no IPOs and few licensing deals meant its companies had limited funding options in 2024. (Shutterstock)